| Eurlex法規(guī)編號(hào)： |
(EU) 2024/2699 |
| OJ編號(hào)： |
OJ L, 2024/2699, 21.10.2024 |
| 中文標(biāo)題： |
2024年10月18日委員會(huì)實(shí)施條例(EU) 2024/2699：根據(jù)歐洲議會(huì)和理事會(huì)條例(EU) 2021/2282，規(guī)定了成員國(guó)衛(wèi)生技術(shù)評(píng)估協(xié)調(diào)小組和委員會(huì)與歐洲藥品管理局合作的詳細(xì)程序規(guī)則，其形式為就醫(yī)藥產(chǎn)品、醫(yī)療器械和體外診斷醫(yī)療器械的聯(lián)合臨床評(píng)估以及醫(yī)藥產(chǎn)品和醫(yī)療器械的聯(lián)合科學(xué)咨詢進(jìn)行信息交流 |
| 原文標(biāo)題： |
Commission Implementing Regulation (EU) 2024/2699 of 18 October 2024 laying down, pursuant to Regulation (EU) 2021/2282 of the European Parliament and of the Council, detailed procedural rules for the cooperation of the Member State Coordination Group on Health Technology Assessment and the Commission with the European Medicines Agency in the form of exchange of information as regards the joint clinical assessment of medicinal products and medical devices and in vitro diagnostic medical devices and as regards the joint scientific consultation on medicinal products and medical devices |
| 發(fā)布日期 |
2024-10-21 |
| 原文鏈接 |
查看歐盟官網(wǎng)文件 |
閱讀：344次
粵公網(wǎng)安備 44010602010620號(hào)